TuesdayMar 05, 2024 3:07 pm

BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company’s candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy…

Continue Reading

TuesdayMar 05, 2024 2:43 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q4 and FY 2023 Results Call

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slated to begin at 4:30 p.m. ET on Wednesday, March 20, 2024, HeartBeam executives will also provide regulatory updates, reviewing ongoing initiatives and anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, Consulting CFO Richard Brounstein, and VP of Regulatory Affairs Deborah Castillo, PhD, will host the call, followed by…

Continue Reading

TuesdayMar 05, 2024 1:54 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North America. Represented by its senior research and clinical development team and co-authored by several of its esteemed scientific advisors, FSD shared the results of its phase 1 clinical study. The results were displayed in a…

Continue Reading

MondayMar 04, 2024 2:35 pm

BioMedNewsBreaks – BioVie Inc. (NASDAQ: BIVI) to Secure ~$21M in Public Offering

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. The company today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share (or pre-funded warrant) and associated warrant. The warrants will have an exercise price of $1.50 per share and will be immediately exercisable for a period of five years following the date…

Continue Reading

MondayMar 04, 2024 2:24 pm

BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Closes on Private Placement Valued at Up to $16M

Biofrontera (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, has closed on a securities purchase agreement. According to the announcement, the agreement is with healthcare-focused institutional investors led by Rosalind Advisors. The financing is for an initial $8 million with an additional $8 million second tranche, dependent on the company reaching specified milestones. The company noted that the funding, along with recent restructuring of a supply agreement, allow it to conduct planned research and development activities as well as support further commercial growth. “The company intends to use the upfront net proceeds from the private placement…

Continue Reading

FridayMar 01, 2024 2:03 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (‘CDC’). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the treatment available on the market addresses symptoms of the…

Continue Reading

ThursdayFeb 29, 2024 10:18 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), presented the results at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in Florida. The results were gathered from the VISIONARY-MS trial long-term open label extension (“LTE”) in participants with stable…

Continue Reading

ThursdayFeb 29, 2024 10:00 am

BioMedNewsBreaks – Ocean Biomedical Inc.’s (NASDAQ: OCEA) Joint Venture Partner to Present First Clinical Study Data at 33rd Annual Meeting of APASL

Ocean Biomedical (NASDAQ: OCEA), a biopharma company that endeavors to accelerate the development of compelling discoveries from top research scientists, congratulates its joint venture partner, Virion Therapeutics, LLC, a clinical-stage biotechnology company developing T cell-based immunotherapies, for the acceptance of its abstract highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure. The abstract was accepted for late breaker oral presentation at the 33rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan, from March 27-31, 2024. “This accepted abstract highlights Virion’s commitment to finding…

Continue Reading

WednesdayFeb 28, 2024 2:48 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Strategic Appointment of Garrett Gardi

HealthLynked (OTCQB: HLYK), a leader in health care technology solutions for patients and providers, has announced the addition of Garrett Gardi to its advisory board. Gardi has more than two decades of experience in employee benefit plans, specializing in predictive cost analytics, consumer-driven platforms, and self-funded/alternative funding methodologies, and brings a wealth of knowledge and expertise to the HealthLynked team. “Garrett’s addition to our advisory board marks a significant milestone for HealthLynked as we continue to expand our reach and impact in the health care sector,” said Dr. Michael Dent, CEO of HealthLynked. “His extensive experience and innovative approach to…

Continue Reading

WednesdayFeb 28, 2024 1:22 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced a debt settlement. According to the announcement, the company’s board of directors approved the settlement of $637,650 owed to arm's length creditors through issuing 545,000 Class B subordinate voting shares in the capital of the corporation; the shares were issued at $1.17 per share. The board also approved the granting of 55,000 restricted share units (“RSUs”) to consultants of the company according to FSD Pharma’s equity incentive plan, with each RSU good for the acquisition of…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050